Baseline characteristics of patients with TIMI 3 (group 1) and TIMI 0–2 (group 2) flow after PTCA
| Group 1 (n = 35) | Group 2 (n = 30) | p Value | |
|---|---|---|---|
| Data are mean (SD) or percentage. | |||
| ACE, angiotensin converting enzyme; CAD, coronary artery disease; MI, myocardial infarction; NS, not significant; NYHA, New York Heart Association; PTCA, percutaneous transluminal coronary angioplasty; TIMI, thrombolysis in myocardial infarction. | |||
| Age (years) | 58 (10) | 54 (9) | NS |
| Male sex | 87% | 81% | NS |
| Family history of CAD | 45% | 48% | NS |
| Hypercholesterolaemia | 26% | 26% | NS |
| Diabetes | 18% | 15% | NS |
| Hypertension | 13% | 16% | NS |
| Smoking | 26% | 25% | NS |
| Previous anterior MI | 55% | 52% | NS |
| Time from index MI to PTCA (months) | 6 (2) | 6 (1) | NS |
| Killip class | |||
| I | 5% | 4% | NS |
| II | 75% | 78% | NS |
| III | 20% | 18% | NS |
| NYHA class | |||
| I | 15% | 12% | NS |
| II | 78% | 80% | NS |
| III | 7% | 8% | NS |
| Treatment before PTCA | |||
| Anticoagulants | 10% | 12% | NS |
| Antiplatelets | 85% | 83% | NS |
| β Blockers | 45% | 48% | NS |
| ACE inhibitors | 11% | 10% | NS |
| Calcium channel blockers | 38% | 36% | NS |
| Treatment at discharge | |||
| Anticoagulants | 11% | 14% | NS |
| Antiplatelets | 98% | 100% | NS |
| β Blockers | 82% | 84% | NS |
| ACE inhibitors | 40% | 45% | NS |
| Calcium channel blockers | 16% | 22% | NS |